← All Signals

🏥 FDA: Wizcure Pharmaa Private Limited — Class II

healthcarebearishSource: FDA
94%Confidence
0Views
FDASource
2026-03-11Date

Summary

Recall of lubricant eye drops due to lack of sterility assurance further implicates Omni Lens as a manufacturer with recurring cGMP violations. This pattern threatens the reliability of multiple ophthalmic product lines under the Vista brand and associated distributors.

Actionable: Investigate the financial and operational impact on distributors like hi-health and consider diversifying away from Omni Lens-sourced ophthalmic products.

AI Confidence: 94%

Data Points

firmWizcure Pharmaa Private Limited
classificationClass II
statusOngoing
distributionDistributed Nationwide in the USA
productVista Tears Polyethylene Glycol 400 0.4% w/v, Propylene Glycol 0.3% w/v Eye Drops, Dry Eye Relief, Lubricant Drops, Sterile 10 ml (1/3 fl. oz.), Manuf

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now